drugset / Trial / NCT04074993
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Phase 2
Unknown
35 enrolled
Ji-youn Han
Seoul National University Bundang Hospital · collabSeoul National University Hospital · collabSeverance Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is single-arm, open-label study design. Patients will receive brigatinib until disease progression, unacceptable toxicity, withdrawal of consent, of death.
Timeline
- Start
- 2020-05-15
- Primary completion
- 2025-01-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigatinib | Small molecule | 180 mg | Oral |